Cargando…

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer

Background: Neither paclitaxel plus trastuzumab (P-H) nor docetaxel-cyclophosphamide plus trastuzumab (TC-H) have been prospectively compared in HER2-positive early-stage breast cancer (EBC). A randomized trial was performed to assess the feasibility of a larger study. Methods: Lower-risk HER2-posit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandes, Ricardo, Ng, Terry L., Alzahrani, Mashari Jemaan, Raphael, Jacques, Blanchette, Phillip, Black, Morgan, Stober, Carol, Pond, Gregory R., Cella, David, Vandermeer, Lisa, Ibrahim, Mohammed, Clemons, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453132/ https://www.ncbi.nlm.nih.gov/pubmed/37623016 http://dx.doi.org/10.3390/curroncol30080535

Ejemplares similares

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design
por: Saunders, Deanna, et al.
Publicado: (2021)

Regularly scheduled physical examinations and the detection of breast cancer recurrences
por: Beltran-Bless, Ana-Alicia, et al.
Publicado: (2023)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation
por: McGee, Sharon, et al.
Publicado: (2021)

Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey
por: Savard, Marie-France, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
por: Tu, Megan M., et al.
Publicado: (2021)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer
por: Awan, Arif, et al.
Publicado: (2020)

Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience
por: Cole, Katherine Marie, et al.
Publicado: (2022)

Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers
por: Cole, Katherine Marie, et al.
Publicado: (2021)

Using machine learning to predict individual patient toxicities from cancer treatments
por: Cole, Katherine Marie, et al.
Publicado: (2022)

The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer
por: Surujballi, Julian, et al.
Publicado: (2021)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
por: Stewart, Paul, et al.
Publicado: (2020)

A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction
por: Arnaout, Angel, et al.
Publicado: (2020)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review
por: Giffoni de Mello Morais Mata, Danilo, et al.
Publicado: (2023)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
por: Clemons, Mark, et al.
Publicado: (2021)

P291 Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers
por: Beltran-Bless, A.-A., et al.
Publicado: (2023)

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression
por: KHALAF, DANIEL, et al.
Publicado: (2014)

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer
por: Addison, C.L., et al.
Publicado: (2016)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

P279 A patient survey evaluating COVID-19-induced changes in follow-up of patients with EBC: opportunities for enhanced evidence-based practice?
por: Beltran-Bless, A.-A., et al.
Publicado: (2023)

Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial
por: Awan, Arif, et al.
Publicado: (2021)

Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program
por: Alshamsan, Bader, et al.
Publicado: (2022)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Lost in Transition? Thoughts on Retirement, Part 2. “Should I Stay or Should I Go Now?”
por: Beltran‐Bless, Ana‐Alicia, et al.
Publicado: (2021)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
por: Kuchuk, I., et al.
Publicado: (2013)

Compliance With Therapeutic Regimens
por: Black, Henry R.
Publicado: (1977)

Optimising weight-loss interventions in cancer patients—A systematic review and network meta-analysis
por: LeVasseur, Nathalie, et al.
Publicado: (2021)

Leaner, Healthier, Happier Together––A Family-Centred Approach to Weight Loss with the Overweight Dog and Her Caregivers
por: Candellone, Alessia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lbpfvu85pc7c4n6hh6r1bhin25